Vivimed Labs Limited
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Vivimed Labs Limited generated cash of $138,120,000, which is less than the previous year. Cash used in financing activities reached the amount of -$162,440,000 last year. Net change in cash is therefore -$34,220,000.
Cash Flow
| 2010 | 551.28M | -71.25M | -593.57M |
|---|---|---|---|
| 2011 | 103.89M | -723.95M | 674.81M |
| 2012 | 451.71M | -4.24B | 4.04B |
| 2016 | 1.54B | -1.90B | 405.88M |
| 2018 | 214.21M | -1.63B | 1.85B |
| 2020 | 795.6M | -1.96B | 724.35M |
| 2021 | 5.67B | 4.03B | -10.15B |
| 2023 | 138.12M | -49.68M | -162.44M |
VIVIMEDLAB.NS Cash Flow Statement (2010 – 2022)
| 2022 | 2020 | 2019 | 2017 | 2015 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 71.84M | 504.88M | 945.04M | 554.73M | 266.71M | 110.96M | 56.21M | 169.75M |
Operating activities | ||||||||
Net income | -3.30B | -757.65M | -1.09B | 857.11M | 999.32M | 631.37M | 488.31M | 310.11M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||
Depreciation and amortization | 1.08B | 554.94M | 669.36M | 564.2M | 613.93M | 237.1M | 91.46M | 87.34M |
Stock-based compensation expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred income tax benefit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | 105.54M | 1.41B | 1.07B | -977.58M | -357.92M | 0 | 0 | 0 |
Inventories | 1.61B | 2.46B | 617.78M | -561.98M | -593.64M | -1.63B | -51.26M | -102.19M |
Accounts payable | 275.19M | -1.92B | -679.23M | 234.01M | 366.8M | 0 | 0 | 0 |
Cash generated by operating activities | 138.12M | 5.67B | 795.6M | 214.21M | 1.54B | 451.71M | 103.89M | 551.28M |
Investing activities | ||||||||
Purchases Of Investments | 0 | -1.13B | -832.02M | 0 | -525.92M | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -49.68M | 0 | -1.12B | -1.63B | -587.02M | -3.61B | -281.37M | -214.5M |
Acquisitions Net | 0 | 5.17B | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -49.68M | 4.03B | -1.96B | -1.63B | -1.90B | -4.24B | -723.95M | -71.25M |
Financing activities | ||||||||
Common Stock Issued | 0 | -3.25B | 9.36M | 3.93B | 0 | 2.21B | 57.61M | 130.53M |
Payments for dividends | 0 | 0 | -13.57M | -39.47M | -116.65M | 0 | -20.33M | -14.95M |
Repurchases of common stock | 0 | -3.25B | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 21.21M | -6.36B | 455.93M | -1.24B | -1.17B | 0 | 0 | 0 |
Cash used in financing activities | -162.44M | -10.15B | 724.35M | 1.85B | 405.88M | 4.04B | 674.81M | -593.57M |
Net Change In Cash | -34.22M | -440.57M | -440.15M | 435.6M | 42.87M | 252.4M | 54.75M | -113.54M |
Cash at end of period | 37.62M | 64.31M | 504.89M | 990.33M | 309.58M | 363.36M | 110.96M | 56.21M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |